CTRI/2023/10/058295尚未招募4 期
Efficacy, Tolerability and Safety Darifenancin versus Mirabegron versus combined therapy of Darifenancin and Mirabegron in patients with Overactive Bladder
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Age =18yrs
- •Patients having symptoms of OAB
排除标准
- •1 Any disease other than OAB that might affect voiding,
- •2 Long QT syndrome, serious heart disease,
- •3 Hypersensitivity to b-agonists or antimuscarinics,
- •4 Surgical therapy that might affect urinary tract function
- •5 Patients not giving consent
研究者
相似试验
尚未招募
4 期
sefulness and safetyOf Cryotherapy versus Bleomycin injection in the treatment of localised keloids.CTRI/2020/08/027352Bankura Sammilani Medical College
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-FRGM Biopharmaceuticals, Inc.150
已完成
不适用
study on low back paiCTRI/2016/10/007348Dr Reddys Laboratories Pvt Ltd
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisEUCTR2019-002341-38-BEGM Biopharmaceuticals, Inc.150
进行中（未招募）
1 期
Phase 2b study evaluating efficacy, safety and tolerability of study drug called NGM282 (Aldafermin) in Patients with Compensated Cirrhosis Due to Nonalcoholic SteatohepatitisCompensated Cirrhosis Due to Nonalcoholic SteatohepatitisMedDRA version: 22.0Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersMedDRA version: 20.1Level: LLTClassification code 10064844Term: Compensated cirrhosisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-002341-38-GBGM Biopharmaceuticals, Inc.150